Table 6.
Drug A | Drug A mode of action | Drug B | Drug B mode of action | Effect (Drug A + Drug B) | References |
---|---|---|---|---|---|
Remdesivir | RdRp inhibitor | Ebselen | Protease inhibitor | Synergistic | (Chen et al., 2021) |
Remdesivir | RdRp inhibitor | Disulfiram | Protease inhibitor | Synergistic | (Chen et al., 2021) |
Remdesivir | RdRp inhibitor | Ivermectin | Importin α/β1 inhibitor | Synergistic | (Tan et al., 2021) |
Remdesivir | RdRp inhibitor | Nitazoxanide | Entry inhibitor | Synergistic | (Bobrowski et al., 2021) |
Nitazoxanide | Entry inhibitor | Umifenovir | Entry inhibitor | Synergistic | (Bobrowski et al., 2021) |
Nitazoxanide | Entry inhibitor | Emetine dihydrochloride hydrate | Replication inhibitor | Synergistic | (Bobrowski et al., 2021) |
Nitazoxanide | Entry inhibitor | Amodiaquine | Entry inhibitor | Synergistic | (Bobrowski et al., 2021) |
Favipiravir | RdRp inhibitor | Ivermectin | Importin α/β1 inhibitor | Synergistic | (Jitobaom et al., 2022) |
Otamixaban | Entry inhibitor | Camostat | TMPRSS2 inhibitor | Synergistic | (Hempel et al., 2021) |
Otamixaban | Entry inhibitor | Nafamostat | TMPRSS2 inhibitor | Synergistic | (Hempel et al., 2021) |
Remdesivir | RdRp inhibitor | Brequinar | Replication inhibitor | Synergistic | (Schultz et al., 2022) |
Molnupiravir | RdRp inhibitor | Brequinar | Replication inhibitor | Synergistic | (Schultz et al., 2022) |
Cepharanthine | Entry inhibitor | Nelfinavir | Replication inhibitor | Synergistic | (Ohashi et al., 2021) |
Remdesivir | RdRp inhibitor | Hydroxychloroquine | Entry inhibitor | Antagonistic | (Bobrowski et al., 2021) |
Remdesivir | RdRp inhibitor | Mefloquine | Entry inhibitor | Antagonistic | (Bobrowski et al., 2021) |
Remdesivir | RdRp inhibitor | Amodiaquine | Entry inhibitor | Antagonistic | (Bobrowski et al., 2021) |
*RdRp = RNA-dependent RNA polymerase, TMPRSS2 = Transmembrane protease, serine 2 |